(Health-NewsWire.Net, August 26, 2016 ) Raloxifene (raloxifene hydrochloride), a non-hormone drug against bone resorption, belongs to the second generation of selective estrogen receptor modulator (SERMs). Different from traditional estrogen replacement therapy (ERT) or hormone replacement therapy (HRT), raloxifene can not only prevent postmenopausal women from osteoporosis but also effectively increase bone mass and bone density so as to treat postmenopausal osteoporosis and prevent osteoporotic fracture. Request sample at : https://marketreportscenter.com/request-sample/133417
When raloxifene made by Eli Lilly under the trade name of Evista entered the market in 1997, its global sales value in the first year reached up to 285 million, making it the second most successful product of Eli Lilly. However, raloxifenes annual sales value has been fluctuating around USD 1 billion after it reached its sales peak of USD 1.091 billion in 2007. Raloxifene made by local enterprises came into the market after Evista entered China in Oct. 2003 and raloxifenes CAGR was about 14% during the period of 2005-2014 according to CRIs survey. Raloxifene enjoys a vast demand in China. Currently, raloxifene in the Chinese market are monopolized by the following three companies: Eli Lilly and Company (Spain), Eli Lilly and Company (UK) and Jiangsu Hengrui Medicine Co., Ltd, among which Eli Lilly and Company (Spain) has the largest market share of 86% for sales value in 2014. Raloxifene market in China is expected to grow in the next few years.
Check for Discount at : https://marketreportscenter.com/request-discount/133417 Readers can get at least the following information from this report: -market size of raloxifene in China -competitive landscape of raloxifene in Chinese market -price of raloxifene made by different enterprises in China -market outlook of raloxifene in China
The author suggests the following groups of people purchase this report: -drug manufacturers -investors/ research institutions interested in Chinese medicine market -any interest in the Chinese medicine market, please contact CRI for customized survey service
Browse full report with TOC : https://marketreportscenter.com/reports/133417/investigation-report-on-china-raloxifene-market-2010-2019
Connect for more details: Sam Collins Market Reports Center Call us : 1-646-883-3044 (US) Email : info@marketreportscenter.com visit our website : https://marketreportscenter.com
Market Reports Center
Sam Collins
1-646-883-3044
sam@marketreportscenter.com
Source: EmailWire.Com
|